Top drugs based on projected 2024 global sales

Keytruda is projected to be the top-ranked drug worldwide based on sales in 2024, with more than 27 billion U.S. dollars. This statistic displays the expected top drugs in 2024 based on sales projections as of December 2023. Due to the patent expiration in the U.S., AbbVie's blockbuster drug Humira will no longer be listed among the top 10 best-selling drugs in 2024.Oncology's Dominance in Pharmaceutical RevenueCancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2024 underscore this trend, while the drug's revenue increased by approximately four billion dollars between 2022 and 2023. This growth is part of a larger pattern in global oncology spending, which reached 218 billion U.S. dollars globally in 2023, more than doubling from 102 billion just six years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030.Market Dynamics and Company PerformanceThe success of drugs like Keytruda is reshaping the pharmaceutical industry's competitive landscape. Merck & Co., Keytruda's manufacturer, has seen its overall revenue increase to 60.1 billion in 2023, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, is expected to drop out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

根据2024年的销售预测，Keytruda预计将成为全球销量排名第一的药物，销售额将超过270亿美元。此统计数据展示了截至2023年12月的销售预测，预计将在2024年成为销量最高的药物。鉴于美国专利到期，艾伯维的畅销药物Humira将不再位列2024年全球销量前十的药物之列。在制药领域，肿瘤学的统治地位日益凸显。Keytruda在2024年的预计销售额凸显了这一趋势，同时该药物从2022年到2023年的收入增长了约40亿美元。这一增长是全球肿瘤学支出增长的一部分，2023年全球肿瘤学支出达到2180亿美元，较六年前增长了超过一倍。对癌症治疗的巨额投资预计将持续下去，像强生、阿斯利康和默克等主要制药公司预计将成为2030年的肿瘤学市场领导者。市场动态和公司业绩，Keytruda等药物的成功正在重塑制药行业的竞争格局。Keytruda的生产商默克公司，其2023年的总营收增长至601亿美元，主要得益于其肿瘤学产品线。该公司对创新的承诺在其2023年创纪录的研发支出中得以体现。这种对研发的专注对于保持行业竞争力至关重要，正如顶级畅销药物排名的变化所证明的那样。例如，由于专利到期，艾伯维的Humira预计将在2024年从销量前十的药物中退出，这凸显了制药公司不断创新和开发新产品以维持其市场地位的不断需求。